Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2011

View Archived Issues

Promising data described from several trials of natalizumab in RRMS

Incyte and Pfizer disclose favorable preclinical data on chemokine CCR2 receptor antagonist

Phase III results show immunogenicity of quadrivalent flu vaccine in children

Actilyse approved in 15 European countries to treat acute ischemic stroke

Nitazoxanide evaluated in viral respiratory infections

Researchers at Novartis disclose new kinesin-like protein KIF11 inhibitors

Novel candidate therapeutics prepared for ophthalmic diseases

Sanofi presents novel protease-activated PAR1 receptor antagonists

New MAP kinase p38 inhibitors designed by RespiVert

NanoViricides raises funds to advance new influenza candidate

Synageva BioPharma and Trimeris complete merger

Acadia Pharmaceuticals clear to test AM-831 in clinic

Novel HIV reverse transcriptase inhibitor prodrugs disclosed

Functional Genetics completes first-in-human FGI-101-1A6 trial

FDA recognizes Velcade extends survival of patients with multiple myeloma

NPS Pharmaceuticals reports topline results from phase III REPLACE study

Evolva clear to begin phase IIa development of EV-077 in diabetic complications

Daiichi Sankyo gains Brazilian rights to drug for overactive bladder

First RENAISSANCE phase III trial does not meet primary endpoint

Pilot study evaluates apremilast in ankylosing spondylitis

Novo Nordisk reports results from Japanese phase IIIa trial of DegludecPlus

FDA approves U.S. market return for Octagam

Artisan Pharma becomes wholly owned subsidiary of Asahi Kasei Pharma

Amgen to pay ImmunoGen milestone for use of TAP technology

Recordati's Normosang approved in Russia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...